| Increased signaling via adenosine A1 receptors, sleep deprivation, imipramine, and ketamine inhibit depressive-like behavior via induction of Homer1a T Serchov, HW Clement, MK Schwarz, F Iasevoli, DK Tosh, M Idzko, ... Neuron 87 (3), 549-562, 2015 | 193 | 2015 |
| Historical and current adenosine receptor agonists in preclinical and clinical development KA Jacobson, DK Tosh, S Jain, ZG Gao Frontiers in cellular neuroscience 13, 124, 2019 | 176 | 2019 |
| Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states JW Little, A Ford, AM Symons-Liguori, Z Chen, K Janes, T Doyle, J Xie, ... Brain 138 (1), 28-35, 2015 | 160 | 2015 |
| A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy KA Jacobson, S Merighi, K Varani, PA Borea, S Baraldi, ... Medicinal research reviews 38 (4), 1031-1072, 2018 | 150 | 2018 |
| Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy K Janes, C Wahlman, JW Little, T Doyle, DK Tosh, KA Jacobson, ... Brain, behavior, and immunity 44, 91-99, 2015 | 139 | 2015 |
| A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways K Janes, E Esposito, T Doyle, S Cuzzocrea, DK Tosh, KA Jacobson, ... Pain 155 (12), 2560-2567, 2014 | 120 | 2014 |
| Controlling murine and rat chronic pain through A3 adenosine receptor activation Z Chen, K Janes, C Chen, T Doyle, L Bryant, DK Tosh, KA Jacobson, ... The FASEB Journal 26 (5), 1855, 2012 | 119 | 2012 |
| Discovery of a New Nucleoside Template for Human A3 Adenosine Receptor Ligands: d-4‘-Thioadenosine Derivatives without 4‘-Hydroxymethyl Group as … LS Jeong, SA Choe, P Gunaga, HO Kim, HW Lee, SK Lee, DK Tosh, ... Journal of medicinal chemistry 50 (14), 3159-3162, 2007 | 96 | 2007 |
| Structure-Guided Design of A3 Adenosine Receptor-Selective Nucleosides: Combination of 2-Arylethynyl and Bicyclo[3.1.0]hexane Substitutions DK Tosh, F Deflorian, K Phan, ZG Gao, TC Wan, E Gizewski, ... Journal of medicinal chemistry 55 (10), 4847-4860, 2012 | 94 | 2012 |
| Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain A Ford, A Castonguay, M Cottet, JW Little, Z Chen, AM Symons-Liguori, ... Journal of Neuroscience 35 (15), 6057-6067, 2015 | 88 | 2015 |
| First Synthesis of 4 ‘-selenonucleosides showing unusual southern conformation LS Jeong, DK Tosh, HO Kim, T Wang, X Hou, HS Yun, Y Kwon, SK Lee, ... Organic Letters 10 (2), 209-212, 2008 | 88 | 2008 |
| Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms C Wahlman, TM Doyle, JW Little, L Luongo, K Janes, Z Chen, E Esposito, ... Pain 159 (6), 1025-1034, 2018 | 83 | 2018 |
| Optimization of adenosine 5′-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening DK Tosh, K Phan, ZG Gao, AA Gakh, F Xu, F Deflorian, R Abagyan, ... Journal of medicinal chemistry 55 (9), 4297-4308, 2012 | 72 | 2012 |
| Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms JL Carlin, S Jain, E Gizewski, TC Wan, DK Tosh, C Xiao, JA Auchampach, ... Neuropharmacology 114, 101-113, 2017 | 68 | 2017 |
| Polyamidoamine (PAMAM) Dendrimer Conjugates of “Clickable” Agonists of the A3 Adenosine Receptor and Coactivation of the P2Y14 Receptor by a Tethered … DK Tosh, LS Yoo, M Chinn, K Hong, SM Kilbey, MO Barrett, IP Fricks, ... Bioconjugate chemistry 21 (2), 372-384, 2010 | 63 | 2010 |
| Medicinal Chemistry of the A3 Adenosine Receptor: Agonists, Antagonists, and Receptor Engineering KA Jacobson, AM Klutz, DK Tosh, AA Ivanov, D Preti, PG Baraldi Adenosine Receptors in Health and Disease, 123-159, 2009 | 63 | 2009 |
| In Vivo Phenotypic Screening for Treating Chronic Neuropathic Pain: Modification of C2-Arylethynyl Group of Conformationally Constrained A3 Adenosine … DK Tosh, A Finley, S Paoletta, SM Moss, ZG Gao, ET Gizewski, ... Journal of medicinal chemistry 57 (23), 9901-9914, 2014 | 60 | 2014 |
| Adenosine A3 agonists reverse neuropathic pain via T cell–mediated production of IL-10 M Durante, S Squillace, F Lauro, LA Giancotti, E Coppi, F Cherchi, ... The Journal of clinical investigation 131 (7), 2021 | 57 | 2021 |
| Discovery of a new template for anticancer agents: 2′-deoxy-2′-fluoro-4′-selenoarabinofuranosyl-cytosine (2′-F-4′-seleno-ara-C) LS Jeong, DK Tosh, WJ Choi, SK Lee, YJ Kang, S Choi, JH Lee, H Lee, ... Journal of medicinal chemistry 52 (17), 5303-5306, 2009 | 56 | 2009 |
| Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain DK Tosh, J Padia, D Salvemini, KA Jacobson Purinergic signalling 11, 371-387, 2015 | 55 | 2015 |
